40 Use and Supply of Drugs or Medicines in Optometric Practice

Size: px
Start display at page:

Download "40 Use and Supply of Drugs or Medicines in Optometric Practice"

Transcription

1 40 Use and Supply of Drugs or Medicines in Optometric Practice Guideline The optometrist has a duty to take due care in the use of drugs in optometric practice and to only supply drugs when it is appropriate to do so. It is good practice for the supply of drugs to normally be made by a pharmacist. Advice General Optometrists are exempt from some of the general rules laid down in the Medicines Act. Two exemptions levels have been established for medicinal products (POMs) that can be sold in the course of professional practice and in an emergency (or supplied via a signed order from the pharmacist 1 ). By virtue of their registration, all optometrists are able to access the basic exemption list. Optometrists who have undergone a further course of training approved by the GOC ( additional supply optometrists ) are able to access an additional list of drugs. Full details of the drugs available on each list are available in the Optometrists Formulary If an optometrist is writing a signed order for supply of the drug by a pharmacist the optometrist must include his/her GOC number on the order. This helps the pharmacist check whether the optometrist is an additional supply optometrist. Optometrists are reminded to use standard abbreviations. Examples are provided in the Optometrists Formulary Practitioners must always act in accordance with the current medicines legislation controlling the use and supply of drugs in optometric practice. Use of drugs in optometric practice Practitioners should ensure they maintain the necessary knowledge and skills to use the drugs they need in optometric practice To protect the patient an optometrist has a duty to maintain a reasonable level of knowledge of drugs e.g. actions, interactions, cautions and contraindications through a commitment to appropriate continuing professional development (see also section below.) Practitioners are encouraged to support adverse drugs reactions reporting schemes (see Information section below). The patient s General Medical Practitioner should be informed of any suspected adverse reaction When using any diagnostic drug, patients should be made aware of the effects and possible side effects of the drug. If the practitioner will not be available to deal with any emergency that may arise following instillation of the drug, he or she should instruct the patient to attend the local Accident and Emergency department should an adverse reaction occur. The College has produced information leaflets that practitioners may wish to give to their patients 3. The College of Optometrists Members Handbook. Pub Jan 08 Revised Jan

2 40.09 Optometrists should record the batch number and expiry date of drugs that are used in their professional practice. This will facilitate verification that the drug is in date and also - in the case of a drug recall makes it easier to trace all patients who may have been affected. The details may be recorded on the patient record, or other suitable log. Supply of drugs in optometric practice Practitioners using or supplying therapeutic drugs should maintain their competence to do this. The competencies are identified in the Competency Framework for Prescribing Optometrists available from the GOC or the National Prescribing Centre In order to separate prescribing and supply, it is good practice for the supply of therapeutic agents to be made by pharmacists wherever possible. Optometrists should not supply therapeutic drugs to patients unless it is in the patient s best interests for them to do so If it is necessary, pharmacy (P) or prescription only (POM) medicines can be supplied to patients but only if this is done by or under the supervision of the optometrist 5. The optometrist should be asked before the drug is sold or supplied to the patient, so that s/he can intervene if this is not appropriate. One way to do this would be to have the supply of drugs only in the consulting room If they are supplying therapeutic drugs to their patients, practitioners have a duty to ensure that this drug is appropriate for the patient. This will mean the optometrist has to make a diagnosis of the patient s condition. Supply should normally only be made following an eye examination, or within a reasonable time afterwards. Patients should be made aware of the need to have their condition periodically reassessed to determine whether or not the drug is still appropriate. This is particularly important if the patient has already sought treatment elsewhere. All actions and advice should be noted on the patient record Optometrists should be aware of the indications, cautions, contraindications and side effects of any medicinal products supplied. Patients should be made aware of how to use the drug and what to do in the case of an adverse event occurring Patients should be asked about any previous drug-induced adverse event and known drug allergies. Self-prescribing and treatment Optometrists should avoid self-prescribing or treatment wherever possible. Exceptions may be when treating minor ailments or taking suitable action in an emergency. Optometrists should not normally prescribe or prepare written orders for POM drugs for their own personal use or that of members of their close family. This is to avoid any lack of objectivity which might arise or potential litigation if things go wrong or relationships break down. Exceptions to this could be where an optometrist was treating minor ailments, or was required to take appropriate action in an emergency. The College of Optometrists Members Handbook. Pub Jan 08 Revised Jan

3 Co-management schemes Optometrists may be involved in co-managing patients, such as those who have undergone surgical procedures. This may involve the optometrist being asked to modify the patient s ocular medication that is not on the list of drugs optometrists can use or supply under the entry level or additional supply level exemptions described above. This may be done under the authority of a Patient Group Direction (see below), or delegated authority from the responsible medical practitioner. Optometrists must ensure that they work within the law and should also ensure that appropriate local protocols are in place. It is important that the optometrist can contact the responsible medical practitioner when needed. Storage and disposal of drugs Optometrists should ensure that all diagnostic and therapeutic drugs are stored according to the manufacturers instructions. They should be out of patients reach Legislation is in place to cover the disposal of hazardous waste. Optometrists must ensure that drug waste is disposed of in accordance with the regulations. This may be via the local pharmacist or GMP surgery or dedicated local service. Information Reporting schemes on adverse drugs reactions From 1 April 2003, the Medicines and Healthcare products Regulatory Agency (MHRA) replaced the Medical Devices Agency (MDA) and the Medicines Control Agency (MCA). The MHRA is an Executive Agency of the Department of Health with trading fund status Two reporting schemes exist, operated by the MHRA. These are the Yellow Card scheme which covers systemic adverse reactions to ocular medicines and ocular reactions to systemic medication and the Medical Devices Reporting Form (covering adverse events to mainly contact lenses and care products) Since the beginning of 1995 certain ophthalmic products such as contact lens care solutions (including contact lens comfort drops), ophthalmic viscoelastic devices, ocular irrigating solutions and ocular endotamponades (used in retinal detachment surgery) have come within the definition of a medical device and therefore are subject to provisions of the Medical Device Regulations (1994) which came fully into force on 14 June Contact lens care products are defined as accessories to contact lenses and therefore are included within the Device Regulations. Products such as artificial tears, diagnostic stains such as fluorescein and rose bengal are not considered devices Full details of the reporting schemes are included in the Optometrists Formulary. Patient Group Directions Optometrists are named as professionals who can supply or administer drugs to patients under a Patient Group Direction (PGD). PGDs are written instructions for the supply or administration of medicines to groups of patients The College of Optometrists Members Handbook. Pub Jan 08 Revised Jan

4 who may not be individually identified before presentation for treatment. Information can be found on the MHRA website 6. The Royal Pharmaceutical Society has produced an information pack for pharmacists 7. Self-prescribing The GMC 8, BMA 9 and RPSGB 10 advise against self-prescribing or treatment wherever possible. Pharmacists Code of Ethics relating to the supply of pharmacy medicines The RPSGB Code of Ethics relating to the sales of pharmacy medicines states that 11 : All staff whose work regularly includes the sale of pharmacy medicines must be competent and instructed to refer customers to the pharmacist where appropriate. (a) Pharmacists or assistants asked for advice on treatment must obtain sufficient information to allow an assessment to be made that self-medication is appropriate, and to enable a suitable product or products to be recommended. Advice on the use of products must be provided. (b) Pharmacists must ensure that when a product is requested by name the procedures for sales of medicines provide for professional advice and intervention whenever this can assist in the safe and effective use of pharmacy medicines. Pharmacists or assistants must provide any advice relevant to the product and the intended consumer. (c) Pharmacists must be personally involved whenever this is necessary to provide an acceptable standard of pharmaceutical care. Assistants must be trained to know when the pharmacist should be consulted. (d) Procedures must ensure that the particular care needed is provided when supplying products for children, the elderly and other special groups or individuals or where the product is for animal use. (e) Pharmacists must ensure that they are involved in the decision to supply any medicine, which requires their intervention. Such medicines may include those that have recently become available without prescription, that may be subject to abuse or misuse, or where the marketing authorisation for nonprescription use is restricted to only selected conditions. Pharmacists and their staff must be aware of the abuse potential of certain over the counter products and should not supply where there are reasonable grounds for suspecting misuse. Additional information The following information is relevant to this section: Royal Pharmaceutical Society of Great Britain, Code of Ethics and standards (accessed 23/3/07) References 1 Guidance on the content of a signed order is available from the AOP _feb04_v5.pdf 2 Optometrists Formulary Accessed 20/12/04 The College of Optometrists Members Handbook. Pub Jan 08 Revised Jan

5 4 Competency framework for prescribing optometrists, General Optical Council & National Prescribing Centre, May and 5 Guidance on Supervision is contained in section 7 of this Guidance para 24 (b) 11 Part 3, service specification 10. The College of Optometrists Members Handbook. Pub Jan 08 Revised Jan

Guidance for optometrist prescribers

Guidance for optometrist prescribers Guidance for optometrist prescribers Contents Introduction Legislation and terminology Standards for optometrist prescribers Specialist areas of practice Section 1 - Guidance for prescribing practice P1.

More information

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment

More information

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH 11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims

More information

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business To facilitate compliance with Regulations 5(1)(d), 5(1)(h) and 10 of the Regulation of Retail

More information

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business to Facilitate Compliance with Regulations 5(1)(g), 6, 8 and 11 of the Regulation of Retail Pharmacy Businesses

More information

Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES

Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES CONTENTS

More information

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health POISONS SCHEDULING Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health Topics Schedules of the Poisons Standard (Cth) Poisons and Therapeutic Goods Act 1966

More information

Response to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014

Response to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014 Responseto ScottishGovernment AConsultationonElectronicCigarettesand StrengtheningTobaccoControlinScotland December2014 Contact Janice Oman Scotland Representation Manager National Pharmacy Association

More information

Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception

Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Pharmaceutical Society of Ireland Version 4 December 2016 Updates made following

More information

CALDERDALE PRIMARY CARE TRUST

CALDERDALE PRIMARY CARE TRUST CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED

More information

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining

More information

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease Evidence-Based Clinical Practice Guideline Treatment & Management of Ocular Disease Effective November 29, 2017 Treatment & Management Of Ocular Disease Clinical Practice Guideline The objective of this

More information

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical

More information

Prescription only medicines (POMs)

Prescription only medicines (POMs) Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Unofficial translation /Ministry of Social Affairs and Health. No. 548/2008. Government Decree on Narcotics Control

Unofficial translation /Ministry of Social Affairs and Health. No. 548/2008. Government Decree on Narcotics Control Unofficial translation /Ministry of Social Affairs and Health No. 548/2008 Government Decree on Narcotics Control Issued in Helsinki on 28 August 2008 Section 1 Scope of application This Decree lays down

More information

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus

More information

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Patient Group Directions Policy

Patient Group Directions Policy Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This

More information

OPTOMETRISTS REGULATION 33/2009

OPTOMETRISTS REGULATION 33/2009 PDF Version [Printer-friendly - ideal for printing entire document] OPTOMETRISTS REGULATION 33/2009 Published by Quickscribe Services Ltd. Updated To: [includes B.C. Reg. 200/2012 amendments (effective

More information

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:

More information

PATIENT GROUP DIRECTION PROCEDURE

PATIENT GROUP DIRECTION PROCEDURE PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen

More information

COPYRIGHTED MATERIAL. Introduction

COPYRIGHTED MATERIAL. Introduction 1 Introduction Pharmacology is the science of drugs and their effects on biological systems. A drug can be defined as a chemical that can cause a change in a biological system; the important biological

More information

Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010

Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010 PHARMACY HOUSE 124 DIXON STREET PO BOX 11 640 WELLINGTON NEW ZEALAND TELEPHONE 04 802 0030 FAX 04 382 9297 EMAIL p.society@psnz.org.nz WEBSITE www.psnz.org.nz 29 September 2010 Clerk of the Health Committee

More information

Recall Guidelines. for Chinese Medicine Products

Recall Guidelines. for Chinese Medicine Products Recall Guidelines for Chinese Medicine Products April 2018 Recall Guidelines for Chinese Medicine Products Chinese Medicines Board Chinese Medicine Council of Hong Kong Compiled in September 2005 1 st

More information

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended

More information

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE This guidance document contains Assured Advice under the ACS Primary Authority Scheme. For more details visit www.acs.org.uk/assured-advice STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE Laws regulating

More information

DIRECT ACCESS - Guidance to BSDHT Members

DIRECT ACCESS - Guidance to BSDHT Members DIRECT CCESS - Guidance to BSDHT Members Direct ccess came into effect from 1 May 2013. But what does it mean for dental hygienists and dental therapists? The GDC have published guidance notes on the subject

More information

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1 1. Introduction Draft Guidance for Pharmacists on Extemporaneous Dispensing Version 1 The purpose of this guidance is to assist pharmacists in discharging their legal and professional obligations to patients

More information

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental

More information

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE Laws regulating the sale of tobacco products across the UK are changing. This guidance outlines how retailers must comply with the new regulations.

More information

Falsified Medicines Directive (FMD) Dispensing Doctors Association Wednesday 18-Oct-17 Jerome Bertin

Falsified Medicines Directive (FMD) Dispensing Doctors Association Wednesday 18-Oct-17 Jerome Bertin Falsified Medicines Directive (FMD) Dispensing Doctors Association Wednesday 18-Oct-17 Jerome Bertin Objectives What is FMD all about and when does it need to happen? Who are SecurMed and what is our role

More information

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines \ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents

More information

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.

More information

Ensuring the gap between science and practice is filled safely - MHRA

Ensuring the gap between science and practice is filled safely - MHRA Safeguarding public health Ensuring the gap between science and practice is filled safely - MHRA Diane Leakey Head of Information and Communications, MHRA April 2012 Agenda Who is MHRA? Why we have regulation?

More information

Recommendations 2. Council is asked to note and discuss the findings of the research and how we intend to use it.

Recommendations 2. Council is asked to note and discuss the findings of the research and how we intend to use it. COUNCIL Survey of contact lens wearers: research findings Meeting: 10 February 2016 Lead responsibility: Alistair Bridge (Director of Strategy) Status: for noting Project manager/paper author: Marie Bunby

More information

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION CLASSIFICATION OF DOCUMENT: PURPOSE: Patient Group Direction Document

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of

More information

How to change the legal classification of a medicine in New Zealand

How to change the legal classification of a medicine in New Zealand How to change the legal classification of a medicine in New Zealand Guidance document Medsafe October 2017 Page 1 of 15 Contents Purpose and scope... 3 Definitions... 3 Background and legislative context...

More information

Guide to Professional Conduct and Ethics for Registered Medical Practitioners. Relationships between doctors and industry Frequently Asked Questions

Guide to Professional Conduct and Ethics for Registered Medical Practitioners. Relationships between doctors and industry Frequently Asked Questions Guide to Professional Conduct and Ethics for Registered Medical Practitioners Relationships between doctors and industry Frequently Asked Questions Partnership Practice Performance Relationships between

More information

HACKNEY NEW SCHOOL DRUGS POLICY

HACKNEY NEW SCHOOL DRUGS POLICY HACKNEY NEW SCHOOL DRUGS POLICY Person(s) responsible Approval requirements Review frequency Headteacher Governors informed of changes Annual Date approved January 2019 Next review due August 2019 1. INTRODUCTION

More information

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD This Patient Group Direction () must only be used by registered pharmacists who have been named and authorized by their organization to practice under it. The most recent and in date final signed version

More information

Writing a PBS-RPBS prescription authorised optometrists

Writing a PBS-RPBS prescription authorised optometrists Writing a PBS-RPBS prescription authorised optometrists www.medicareaustralia.gov.au Writing a PBS prescription authorised optometrists PBS items you are able to prescribe as an authorised optometrist

More information

MECS and Prescribing. Jane Bell BSc FCOptom, DipTpIP, Dip Glauc

MECS and Prescribing. Jane Bell BSc FCOptom, DipTpIP, Dip Glauc MECS and Prescribing Jane Bell BSc FCOptom, DipTpIP, Dip Glauc Discussion House Rules Open discussion with everyone participating Respect the view of others; do not criticise or judge There are no right

More information

Guidelines on the Counselling and Medicine Therapy Review in the Supply of Prescribed Medicinal Products from a Retail Pharmacy Business

Guidelines on the Counselling and Medicine Therapy Review in the Supply of Prescribed Medicinal Products from a Retail Pharmacy Business Guidelines on the Counselling and Medicine Therapy Review in the Supply of Prescribed Medicinal Products from a Retail Pharmacy Business to facilitate compliance with Regulation 9 of the Regulation of

More information

Ontario s Narcotics Strategy

Ontario s Narcotics Strategy Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action

More information

Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING. Summary

Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING. Summary NHS: PCA(O)(2013)4 Health and Social Care Integration Directorate Primary Care Division Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING Summary 1. This letter advises NHS Boards

More information

Pharmaceutical System in the UK

Pharmaceutical System in the UK Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose

More information

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide

More information

GUILSBOROUGH ACADEMY DRUGS EDUCATION POLICY

GUILSBOROUGH ACADEMY DRUGS EDUCATION POLICY GUILSBOROUGH ACADEMY DRUGS EDUCATION POLICY Policy Name Owner Statutory Vice Principal (Pastoral) No Date Ratified Review Due July 2018 July 2019 POLICY Guilsborough Academy recognises the effect of the

More information

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts. PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This

More information

A themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008

A themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008 A themed review of patient safety incidents involving anti-cancer medicines 1 November 2003 30 June 2008 October 2010 Executive Summary National Patient Safety Agency 2010. Copyright and other intellectual

More information

SINGLE USE MEDICAL DEVICES POLICY

SINGLE USE MEDICAL DEVICES POLICY SINGLE USE MEDICAL DEVICES POLICY First Issued by/date BWW /BKW March 2001 Issue Version Purpose of Issue/Description of Change Planned Review Date 2 Update May 2011 Named Responsible Officer:- Approved

More information

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone Package leaflet: information for the user OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone Read all of this leaflet carefully before you are given this medicine because it contains

More information

Falsified Medicines Directive - Safety Features Update

Falsified Medicines Directive - Safety Features Update Falsified Medicines Directive - Safety Features Update Catherine Neary GMP Conference 12 th November 2014 Agenda Background Delegated Act(s) Proposals Under Consideration White List & Black List Next Steps

More information

MEDICINES CONTROL AGENCY. Guideline for Dispensing of Medicines

MEDICINES CONTROL AGENCY. Guideline for Dispensing of Medicines MEDICINES CONTROL AGENCY Guideline for Dispensing of Medicines FORWARD The Medicines Control Agency (MCA) established by an Act of Parliament and assented to on 24th December 2014 is mandated to regulate

More information

DIRECT ACCESS Guidance to BSDHT Members

DIRECT ACCESS Guidance to BSDHT Members DIRECT CCESS Guidance to BSDHT Members Direct ccess comes into effect from 1 May 2013. But what does it mean for dental hygienists and dental therapists? The GDC have published guidance notes on the subject

More information

On successful completion of the Unit the learner will be able to:

On successful completion of the Unit the learner will be able to: Higher National Unit specification General information Unit code: H9R8 34 Superclass: PF Publication date: September 2015 Source: Scottish Qualifications Authority Version: 03 Unit purpose This Unit is

More information

Workplace Drug and Alcohol Policy

Workplace Drug and Alcohol Policy Workplace Drug and Alcohol Policy January 2017 This Drug and Alcohol Policy is intended for and includes but is not limited to all Students, Contractors and all others either directly or indirectly engaged

More information

Changing practice to support service delivery

Changing practice to support service delivery Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction

More information

WORKERS IN A NUCLEAR FACILITY

WORKERS IN A NUCLEAR FACILITY OCCUPATIONAL EXPOSURE AND CATEGORIZATION OF WORKERS IN A NUCLEAR FACILITY Celso Osimani 8 th International Summer School on Nuclear Decommissioning and Waste Management JRC-Ispra, Italy, 12-16 September

More information

Script for audio: Pseudoephedrine and ephedrine. Audiovisual training for pharmacy support staff

Script for audio: Pseudoephedrine and ephedrine. Audiovisual training for pharmacy support staff Script for audio: Pseudoephedrine and ephedrine Audiovisual training for pharmacy support staff The aim of this presentation is to provide you with information about the changes that are taking place to

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES APPLICATION FOR RECLASSIFICATION ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES Part A Classification Change Sought 1. International Non-Proprietary name of Medicine fluocortolone pivalate, fluocortolone

More information

A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE

A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Revision January 2006 A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR

More information

Care homes - Homely remedies

Care homes - Homely remedies Bulletin 72 August 2014 Care homes - Homely remedies Care home staff have a recognised duty of care to be able to respond to minor symptoms experienced by residents. A homely remedy is a medicinal product

More information

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 January 19, 2018 Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 By email: cannabis@canada.ca RE: Proposed Approach to the Regulation of Cannabis

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection UNCONTROLLED WHEN PRINTED EFFECTIVE FROM OCTOBER 2008 REVIEW DATE

More information

All Saints First School Administering of Medicines Policy

All Saints First School Administering of Medicines Policy All Saints First School Administering of Medicines Policy Success Indicators The following indicators will demonstrate the level of compliance with this policy and its procedures: a) Employees who are

More information

Guidance for Pharmacists on Extemporaneous Dispensing

Guidance for Pharmacists on Extemporaneous Dispensing Guidance for Pharmacists on Extemporaneous Dispensing Pharmaceutical Society of Ireland Version 1 June 2015 Contents 1. Introduction 2 2. Legislative Basis and Implications 3 3. Guidance 4 3.1 Key Responsibilities

More information

PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine

PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu Primary and Community Care Directorate Pharmacy Division T: 0131-244 2528 F: 0131-244 2375 E: irene.foster@scotland.gsi.gov.uk 26 March 2008 abcdefghijklmnopqrstu Directors of Pharmacy Chief Executives,

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is

More information

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This

More information

Information about cases being considered by the Case Examiners

Information about cases being considered by the Case Examiners Information about cases being considered by the Case Examiners 13 October 2016 1 Contents Purpose... 3 What should I do next?... 3 Background... 4 Criteria that Case Examiners will consider... 5 Closing

More information

Health (Tobacco, Nicotine etc. and Care)(Scotland) Bill. Japan Tobacco International (JTI)

Health (Tobacco, Nicotine etc. and Care)(Scotland) Bill. Japan Tobacco International (JTI) Health (Tobacco, Nicotine etc. and Care)(Scotland) Bill Organisation name Japan Tobacco International (JTI) Japan Tobacco International (JTI) is part of the Japan Tobacco group (JT Group) of companies,

More information

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

Paediatric Prescribing Pocket Guide September 2014 (Version 1) PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors

More information

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK Presented by: Mariam Aslam ESCOP European Scientific Cooperative On Phytotheapy (ESCOP) Founded in June 1989 as an umbrella

More information

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis

More information

Name of Event: Date of Event: Details of Event Organiser: [Name, Address, Contact number, ]

Name of Event: Date of Event: Details of Event Organiser: [Name, Address, Contact number,  ] FOOD SAFETY PLAN [Template] - Please complete the missing details and change or add to this plan as required so that it is specific to your event and covers all the food safety issues at your event. -

More information

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of

More information

medicines and side effects

medicines and side effects human medicines our advice on medicines and side effects medicines title and side effects Medicines can help people live longer and healthier lives. They can help cure or treat an illness or disease and

More information

Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes

Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes This good practice guidance is intended to be used as a framework for care home managers to adapt when writing their

More information

This is an unofficial English translation of the Royal Decree 1344/2007 revised by the Spanish Agency for Medicines and Medical Devices

This is an unofficial English translation of the Royal Decree 1344/2007 revised by the Spanish Agency for Medicines and Medical Devices agencia española de medicamentos y productos sanitarios This is an unofficial English translation of the Royal Decree 1344/2007 revised by the Spanish Agency for Medicines and Medical Devices ROYAL DECREE

More information

PATIENT GROUP DIRECTION (PGD)

PATIENT GROUP DIRECTION (PGD) PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:

More information

REGULATION (EC) No.141/2000

REGULATION (EC) No.141/2000 REGULATION (EC) No.141/2000 Community legislation in force Document 300R0141 Directory chapters where this document can be found: [15.30 Health promotion] Regulation (EC) No.141/2000 of the European Parliament

More information

ACCESS TO NON-PRESCRIPTION MEDICINES THE KEY ROLE OF PHARMACY IN SELF-CARE

ACCESS TO NON-PRESCRIPTION MEDICINES THE KEY ROLE OF PHARMACY IN SELF-CARE ACCESS TO NON-PRESCRIPTION MEDICINES THE KEY ROLE OF PHARMACY IN SELF-CARE GIRP Position Paper 1. Background Non-prescription medicines (NPMs), also referred to as Over-the-Counter medicines (OTCs), are

More information

Herbal medicines and supplements for cancer patients

Herbal medicines and supplements for cancer patients Herbal medicines and supplements for cancer patients Questions and answers Information for patients Pharmacy page 2 of 8 This leaflet is for all patients having treatment for cancer who are taking or thinking

More information

Substance use and misuse

Substance use and misuse An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER

More information

PATIENT GROUP DIRECTIONS POLICY

PATIENT GROUP DIRECTIONS POLICY PATIENT GROUP DIRECTIONS POLICY To be read in conjunction with the Medicines Policy and the Controlled Drugs Policy Version: 5 Ratified by: Senior Managers Operations Group Date ratified: August 2015 October

More information

Lincolnshire Prescribing and Clinical Effectiveness Bulletin

Lincolnshire Prescribing and Clinical Effectiveness Bulletin S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,

More information

This document expires on Patient Group Direction No. VI 7

This document expires on Patient Group Direction No. VI 7 Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed

More information

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Acute & Emergency Care November 2016 Association of Health Professions in Ophthalmology General

More information

Alcohol and Substance Policy

Alcohol and Substance Policy Alcohol and Substance Policy Lead Manager Responsible Director Approved by Kenneth Fleming, Head of Health & Safety Anne MacPherson, Director of Human Resource and Organisational Development Health & Safety

More information

This document expires on Patient Group Direction No. VI 5

This document expires on Patient Group Direction No. VI 5 Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between

More information